AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, has announced a new pipeline program in collaboration with a leading global pharmaceutical company.

Through this partnership, a single-injection, long-acting biologic will be developed using AmacaThera’s advanced hydrogel delivery platform, AmacaGel, in combination with the partner’s therapeutic. Co-funded by both organizations, the initiative will leverage their complementary strengths and resources to accelerate the development of this innovative biologic.

“We are thrilled to collaborate on this promising venture,” said Molly Shoichet, Chief Scientific Officer at AmacaThera. “This partnership allows us to utilize AmacaThera’s deep expertise in delivery to achieve success with novel biologics. Our core technology has been rigorously tested at AmacaThera and the University of Toronto with a wide range of therapeutics – including small molecules, biologics and stem cells.”

This announcement follows the recent release of Phase 1 data from AmacaThera’s successful first-in-human study, which evaluated AmacaGel in combination with an anesthetic. The study generated valuable human data on both the core platform and its integration with a therapeutic payload.

The partnership was facilitated by CQDM’s Connect-Pharma series, which provides Canadian companies and academics the opportunity to connect with representatives from CQDM’s global pharmaceutical members.